The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptorLivia Stanger, Michael Holinstat, Kiran Kumar et al.|Blood|2023Cited by 18
HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of BleedingLivia Stanger, Björn Dahlöf, Sylviane Lambert et al.|Blood|2023Cited by 1
CS585 IS A NOVEL ORALLY AVAILABLE PROSTACYCLIN RECEPTOR AGONIST WITH LONG-TERM IN VIVO INHIBITION OF PLATELETS AND THROMBOSIS FORMATION IN MOUSE WITHOUT INCREASED RISK OF BLEEDINGMichael Holinstat, Björn Dahlöf, Adriana Yamaguchi et al.|Journal of the American College of Cardiology|2023Cited by 0
Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosisLivia Stanger, Michael Holinstat, Sylviane Lambert et al.|European Heart Journal|2023Cited by 0
CS585 Demonstrates Favorable Selectivity and Sustained <i>In Vivo</i> Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor AgonistsLivia Stanger, Michael Holinstat, Sylviane Lambert et al.|Blood|2023Cited by 0